Original languageEnglish
JournalJournal of Nuclear Medicine
DOIs
Publication statusE-pub ahead of print - 4 Oct 2019

Cite this

@article{e20a435125fd4f8cb3c12b57a6520eff,
title = "ABCG2- and ABCB1 inhibition using supratherapeutic doses of erlotinib: clinical implications in the treatment of CNS metastases",
author = "{van de Stadt}, {Eveline A.} and Maqsood Yaqub and Idris Bahce and Hendrikse, {N. H.}",
year = "2019",
month = "10",
day = "4",
doi = "10.2967/jnumed.119.235705",
language = "English",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",

}

TY - JOUR

T1 - ABCG2- and ABCB1 inhibition using supratherapeutic doses of erlotinib

T2 - clinical implications in the treatment of CNS metastases

AU - van de Stadt, Eveline A.

AU - Yaqub, Maqsood

AU - Bahce, Idris

AU - Hendrikse, N. H.

PY - 2019/10/4

Y1 - 2019/10/4

UR - http://www.mendeley.com/research/abcg2-abcb1-inhibition-using-supratherapeutic-doses-erlotinib-clinical-implications-treatment-cns-me

U2 - 10.2967/jnumed.119.235705

DO - 10.2967/jnumed.119.235705

M3 - Article

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

ER -